NCT03361098View on ClinicalTrials.gov

DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2

PHASE4CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

September 18, 2017

Primary Completion Date

November 25, 2019

Study Completion Date

March 25, 2020

Conditions
Type 2 Diabetes MellitusObesity
Interventions
DRUG

Dapagliflozin 10mg

Dapagliflozin 10mg oral tablet once daily

DRUG

Exenatide

Exenatide 5 microgram b.i.d. week 1-4 Exenatide 10 microgram b.i.d. week 5-16

OTHER

placebo exenatide

placebo b.i.d. exenatide

OTHER

placebo dapagliflozin

placebo tablets dapagliflozin

Trial Locations (1)

1081 HV

Amsterdam UMC, location VU Medical Center, Amsterdam

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Amsterdam UMC, location VUmc

OTHER